ARGX-117 (anti-Complement C2) a humanized inhibitory monoclonal antibody against complement C2. ARGX-117 (anti-Complement C2) prevents the formation of the C3 proconvertase and inhibits classical and lectin pathway activation upstream of C3 activation through binding to the Sushi-2 domain of C2. ARGX-117 (anti-Complement C2) exhibits pH- and calcium-dependent target binding. ARGX-117 (anti-Complement C2) prevents complement-mediated cytotoxicity in in vitro models for autoimmune hemolytic anemia and antibody-mediated rejection of organ transplants. Purity ≥95% (SDS-PAGE&SEC) Endotoxin Level ≤1.0EU/mg Protein Function Component C2 which is part of the classical pathway of the complement system is cleaved by activated factor C1 into two fragments: C2b and C2a. C2a, a serine protease, then combines with complement factor 4b to generate the C3 or C5 convertase.
Product Properties
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
146.12 kDa
Purification Method
Protein A purified
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
2579031-19-7
Images
ARGX-117 (anti-Complement C2) (Ab190121) - ELISA Immobilized Human Complement C2 Protein at 2.0 μg/mL can bind ARGX-117 (anti-Complement C2) (Ab190121) with the EC
₅₀
of 41.04 ng/mL.
ARGX-117 (anti-Complement C2) (Ab190121) - SEC The purity of ARGX-117 (anti-Complement C2) (Ab190121) is more than 95% verified by HPLC.